Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
暂无分享,去创建一个
D. Shin | Y. Bang | J. Ji | Jin-Hyuk Choi | Hyung‐Ho Kim | Hoon-Kyo Kim | Jen‐Shi Chen | I. Chung | H. Chung | S. Noh | Han-Kwang Yang | Sook Ryun Park | Wansik Yu | S. Ha | Sang-Woon Kim | Jong Inn Lee | Y. Lim | Hyung-Ho Kim | Hoon‐Kyo Kim
[1] R. Labianca,et al. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] R. Labianca,et al. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. , 2014 .
[3] Wei-Guo Zhu,et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[4] Y. Bang,et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial , 2012, The Lancet.
[5] Joon-Oh Park,et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Y. Ohashi,et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] R. Labianca,et al. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] F. D. De Braud,et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Inoue,et al. Gastric Cancer Working Group report. , 2010, Japanese journal of clinical oncology.
[10] D. Sargent,et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. , 2010, JAMA.
[11] H. Putter,et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. , 2010, The Lancet. Oncology.
[12] D. Cunningham,et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] W. Scheithauer,et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Yasuo Ohashi,et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. , 2007, The New England journal of medicine.
[15] C. V. D. van de Velde,et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.
[16] Jen-Hao Chen,et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. , 2006, The Lancet. Oncology.
[17] M. Bains,et al. Patterns of Initial Recurrence in Completely Resected Gastric Adenocarcinoma , 2004, Annals of surgery.
[18] S. Lo,et al. Incidence and Factors Associated with Recurrence Patterns after Intended Curative Surgery for Gastric Cancer , 2003, World Journal of Surgery.
[19] W. Allum,et al. Guidelines for the management of oesophageal and gastric cancer , 2002, Gut.
[20] Aller,et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2002, The New England journal of medicine.
[21] Y. Kodera,et al. The number of metastatic lymph nodes: a promising prognostic determinant for gastric carcinoma in the latest edition of the TNM classification. , 1998, Journal of the American College of Surgeons.
[22] Y. Maehara,et al. Prognostic significance of the number of positive lymph nodes in gastric carcinoma , 1994, The British journal of surgery.